Salts and crystalline forms of a PD-1/PD-L1 inhibitor

US11866451B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Zhongjiang Jia · Kennett Square, US
• Shili Chen · Cheshire, US
• Yi Li · Shanghai, CN
• Timothy P. Martin · Noblesville, US
• Bo Shen · Ward, US
• Naijing Su · Hockessin, US
• Jiacheng Zhou · Shanghai, CN
• Qun Li · Beijing, CN

Key dates

• Filing date: Nov 10, 2020
• Grant date: Jan 9, 2024
• Expiry date: May 7, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/42
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.